225 related articles for article (PubMed ID: 21837669)
1. Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers.
Raghav KP; Hernandez-Aya LF; Lei X; Chavez-Macgregor M; Meric-Bernstam F; Buchholz TA; Sahin A; Do KA; Hortobagyi GN; Gonzalez-Angulo AM
Cancer; 2012 Mar; 118(6):1498-506. PubMed ID: 21837669
[TBL] [Abstract][Full Text] [Related]
2. The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone.
Campbell EJ; Tesson M; Doogan F; Mohammed ZMA; Mallon E; Edwards J
Br J Cancer; 2016 Oct; 115(8):967-973. PubMed ID: 27657341
[TBL] [Abstract][Full Text] [Related]
3. Progesterone receptor status in determining the prognosis of estrogen receptor positive/ HER2 negative breast carcinoma patients.
Bal O; Yalcintas Arslan U; Durnali A; Uyetrk U; Demirci A; Tastekin D; Ekinci A; Esbah O; Turker I; Uysal Sonmez O; Oksuzoglu B
J BUON; 2015; 20(1):28-34. PubMed ID: 25778292
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
5. Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer.
Chen XS; Ma CD; Wu JY; Yang WT; Lu HF; Wu J; Lu JS; Shao ZM; Shen ZZ; Shen KW
Tumori; 2010; 96(1):103-10. PubMed ID: 20437866
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
Parise CA; Bauer KR; Brown MM; Caggiano V
Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
[TBL] [Abstract][Full Text] [Related]
7. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
8. Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients.
Ilgun S; Sarsenov D; Erdogan Z; Ordu C; Celebi F; Nur Pilanci K; Ozturk A; Selamoglu D; Alco G; Aktepe F; Eralp Y; Tuzlali S; Ozmen V
J BUON; 2016; 21(6):1425-1432. PubMed ID: 28039703
[TBL] [Abstract][Full Text] [Related]
9. Molecular phenotypes of DCIS predict overall and invasive recurrence.
Williams KE; Barnes NLP; Cramer A; Johnson R; Cheema K; Morris J; Howe M; Bundred NJ
Ann Oncol; 2015 May; 26(5):1019-1025. PubMed ID: 25678586
[TBL] [Abstract][Full Text] [Related]
10. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
11. Single hormone receptor-positive breast cancer patients experienced poor survival outcomes: a systematic review and meta-analysis.
Wu N; Fu F; Chen L; Lin Y; Yang P; Wang C
Clin Transl Oncol; 2020 Apr; 22(4):474-485. PubMed ID: 31222450
[TBL] [Abstract][Full Text] [Related]
12. Age related influence of triple receptor status on metastatic breast cancer post relapse survival.
Todorovic-Rakovic N; Neskovic-Konstantinovic Z
J BUON; 2013; 18(4):851-8. PubMed ID: 24344008
[TBL] [Abstract][Full Text] [Related]
13. Prognostic features of breast cancer differ between women in the Democratic Republic of Congo and Belgium.
Luyeye Mvila G; Batalansi D; Praet M; Marchal G; Laenen A; Christiaens MR; Brouckaert O; Ali-Risasi C; Neven P; Van Ongeval C
Breast; 2015 Oct; 24(5):642-8. PubMed ID: 26279132
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers.
Micello D; Marando A; Sahnane N; Riva C; Capella C; Sessa F
Virchows Arch; 2010 Oct; 457(4):467-76. PubMed ID: 20809337
[TBL] [Abstract][Full Text] [Related]
15. Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
Liu XY; Ma D; Xu XE; Jin X; Yu KD; Jiang YZ; Shao ZM
Theranostics; 2018; 8(22):6386-6399. PubMed ID: 30613307
[TBL] [Abstract][Full Text] [Related]
16. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
[TBL] [Abstract][Full Text] [Related]
17. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.
Konecny G; Pauletti G; Pegram M; Untch M; Dandekar S; Aguilar Z; Wilson C; Rong HM; Bauerfeind I; Felber M; Wang HJ; Beryt M; Seshadri R; Hepp H; Slamon DJ
J Natl Cancer Inst; 2003 Jan; 95(2):142-53. PubMed ID: 12529347
[TBL] [Abstract][Full Text] [Related]
18. Survival outcome of weak estrogen/progesterone receptor expression in HER2 negative breast cancer is similar to triple negative breast cancer.
Liao GS; Dai MS; Hsu HM; Chu CH; Hong ZJ; Fu CY; Chou YC; Huang TC; Yu JC
Eur J Surg Oncol; 2017 Oct; 43(10):1855-1861. PubMed ID: 28756019
[TBL] [Abstract][Full Text] [Related]
19. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study.
Puig-Vives M; Sánchez MJ; Sánchez-Cantalejo J; Torrella-Ramos A; Martos C; Ardanaz E; Chirlaque MD; Perucha J; Díaz JM; Mateos A; Machón M; Marcos-Gragera R
Gynecol Oncol; 2013 Sep; 130(3):609-14. PubMed ID: 23747837
[TBL] [Abstract][Full Text] [Related]
20. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA.
Lund MJ; Trivers KF; Porter PL; Coates RJ; Leyland-Jones B; Brawley OW; Flagg EW; O'Regan RM; Gabram SG; Eley JW
Breast Cancer Res Treat; 2009 Jan; 113(2):357-70. PubMed ID: 18324472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
